Recursion Pharmaceuticals

Recursion Pharmaceuticals EBIT Margin

The EBIT Margin (Operating Margin) of Recursion Pharmaceuticals (RXRX) as of Nov 11, 2026 is -867.87 %. In the previous year, EBIT Margin (Operating Margin) was -814.09 % — a change of 6.61% (lower).

EBIT Margin

-867.87 %

YoY

6.61%

Last updated:

EBIT Margin (Operating Margin) of Recursion Pharmaceuticals is 2025 -867.87 % . EBIT Margin (Operating Margin) of Recursion Pharmaceuticals was 2024 -814.09 % . It decreases by 6.61% lower compared to the previous year.

Recursion Pharmaceuticals's operating (EBIT) margin stands at -867.9%, up from -1,836.0% several years earlier.

The Recursion Pharmaceuticals EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-3,649.39 USD
Jan 1, 2020
-2,519.25 USD
Jan 1, 2021
-1,836.00 USD
Jan 1, 2022
-619.26 USD
Jan 1, 2023
-797.84 USD
Jan 1, 2024
-814.09 USD
Jan 1, 2025
-867.87 USD
The Recursion Pharmaceuticals EBIT Margin history
YEAREBIT MarginYoY
-867.87 %+6.61%
-814.09 %+2.04%
-797.84 %+28.84%
-619.26 %-66.27%
-1,836.00 %-27.12%
-2,519.25 %-30.97%
-3,649.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

EBIT Margin (Operating Margin) of Recursion Pharmaceuticals is -867.87 % in 2025.

EBIT Margin (Operating Margin) of Recursion Pharmaceuticals changed from -814.09 % to -867.87 %, representing a 6.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Recursion Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Recursion Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Recursion Pharmaceuticals